Previous studies have shown that epigenetic silencing of ERα is a major mechanism for ER negative phenotypes in breast cancer cells (7, 11) and the reversible nature of this mechanism may provide new therapeutic avenues for ER negative breast tumors (13, 20). This evidence concerns the gene ESR1 and breast cancer.